This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sato, T. Articles by Niitsu, Y. Search for Related Content PubMed PubMed Citation Articles by Sato, T. Articles by Niitsu, Y.

An Apoptosis-inducing Gene Therapy for Pancreatic Cancer with a Combination of 55-kDa Tumor Necrosis Factor (TNF) Receptor Gene Transfection and Mutein TNF Administration

Fourth Department of Internal Medicine [T. S., N. Y., H. S., M. T., T. O., S. S., Y. N.] and Department of Laboratory Diagnosis [N. W.], Sapporo Medical University, School of Medicine, Sapporo 060, Japan

Intratumoral injection of recombinant human tumor necrosis factor (TNF) for inoperable pancreatic cancer has shown some efficacy in suppressing tumor growth or decreasing tumor markers. However, complete regression has not yet been achieved, possibly due to a lack of TNF receptors on tumor cells or an abundance of intracellular resistance factors. Recently, two distinct types of TNF receptors, R55 and R75, were identified, which are responsible for signaling of cytotoxicity and of proinflammation, respectively. In this study, a novel type of suicide gene therapy is proposed that is based on transfection of the R55 gene into human pancreatic cancer cells (AsPC-1 and PANC-1) and subsequent administration of TNF. The transfectants from both cell lines showed higher TNF susceptibility than their parental cells. In vivo tumor formation of an AsPC-1 clone (clone 10) inoculated in nude mice was substantially suppressed by administration of TNF.

For practical use of this strategy, however, the adverse effects of TNF may become an obstacle. We previously produced mutein TNF 471, which had a higher affinity for R55, superior antitumor activity, and fewer adverse effects. This mutein TNF 471 manifested greater antitumor activity against clone 10.

Because the R55 receptor is known to be involved in augmentation of cellular immunity by TNF, mutein TNF 471 is also expected to be highly potent in this function. In fact, the mutein TNF 471 induced higher splenic natural killer cell activity in nude mice inoculated with clone 10 than did native TNF. This property of augumenting cellular responses may be advantageous in the eradication of viable tumor cells left untransfected in practical gene therapy regimens in which 100% transfection of the R55 gene into tumors is not feasible.

Thus, gene therapy combining transfection of the TNF-R55 gene with administration of mutein TNF 471 may provide a new modality for the treatment of pancreatic cancer.

¹ To whom requests for reprints should be addressed, at Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine, South-1, West-16, Chuo-ku, Sapporo, Japan 060.

Received 9/16/97. Accepted 2/13/98.

This article has been cited by other articles:

				C. Rae, S. Langa, S. J. Tucker, and D. J. MacEwan Elevated NF-{kappa}B responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis PNAS, July 31, 2007; 104(31): 12790 - 12795. [Abstract] [Full Text] [PDF]

				G. J. Ullenhag, I. Spendlove, N. F.S. Watson, A. A. Indar, M. Dube, R. A. Robins, C. Maxwell-Armstrong, J. H. Scholefield, and L. G. Durrant A Neoadjuvant/Adjuvant Randomized Trial of Colorectal Cancer Patients Vaccinated with an Anti-Idiotypic Antibody, 105AD7, Mimicking CD55 Clin. Cancer Res., December 15, 2006; 12(24): 7389 - 7396. [Abstract] [Full Text] [PDF]

				W.-H. Shen, J.-H. Zhou, S. R. Broussard, G. G. Freund, R. Dantzer, and K. W. Kelley Proinflammatory Cytokines Block Growth of Breast Cancer Cells by Impairing Signals from a Growth Factor Receptor Cancer Res., August 15, 2002; 62(16): 4746 - 4756. [Abstract] [Full Text] [PDF]

				F. Bazzoni and E. Regalia Triggering of Antitumor Activity Through Melanoma-specific Transduction of a Constitutively Active Tumor Necrosis Factor (TNF) R1 Chimeric Receptor in the Absence of TNF-{{alpha}} Cancer Res., February 1, 2001; 61(3): 1050 - 1057. [Abstract] [Full Text]

				M. F. X. Gnant, A. C. Berger, J. Huang, M. Puhlmann, P. C. Wu, M. J. Merino, D. L. Bartlett, H. Richard Alexander, and S. K. Libutti Sensitization of Tumor Necrosis Factor {{alpha}}-resistant Human Melanoma by Tumor-specific in Vivo Transfer of the Gene Encoding Endothelial Monocyte-activating Polypeptide II Using Recombinant Vaccinia Virus Cancer Res., September 1, 1999; 59(18): 4668 - 4674. [Abstract] [Full Text] [PDF]